Nectar Lifesciences Limited has submitted its Letter of Offer for the buyback of equity shares. The company plans to repurchase 3,00,00,000 (Three Crore) fully paid-up equity shares at a price of ₹27 per share, amounting to a total buyback value of ₹81,00,00,000 (Eighty-One Crore Rupees). The buyback will be conducted on a proportionate basis through the tender offer route. The record date for determining eligible shareholders and their buyback entitlement was Wednesday, December 24, 2025. The buyback offer opens on Wednesday, December 31, 2025, and closes on Tuesday, January 06, 2026. This buyback represents 13.38% of the company's existing paid-up equity capital. The buyback size is 9.00% of the aggregate of the total paid-up equity share capital and free reserves as of March 31, 2025. The company will transfer a sum equal to the nominal value of the bought-back shares to a capital redemption reserve account. A specific reservation of 15% of the buyback shares is made for small shareholders.